ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

Drugmaker GSK (GlaxoSmithKline) has said it is “well positioned” to cope with any financial impact from changes to US tariff rules. It came as the FTSE 100 giant revealed a rise in sales as weakness ...

Net Sales at Rs 966.08 crore in March 2025 up 6.06% from Rs. 910.87 crore in March 2024. Quarterly Net Profit at Rs. 260.14 ...

The company is working closely with the contract manufacturing facility for resumption of operations. Shares of ...

GlaxoSmithKline Pharmaceuticals, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹2827.05. The stock has experienced fluctuations ...

Arizona sued drug manufacturer GlaxoSmithKline over what it calls deceptive practices involving the inhaled corticosteroid Flovent that endangered asthma patients. The lawsuit filed Thursday in ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/16/25, Coca-Cola Europacific Partners plc (Symbol: CCEP), Smurfit Westrock plc (Symbol: SW), and Glaxosmithkline plc (Symbol ...

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as Glindia Limited in November, 1924. The Company s name was changed to Glaxo (India) Limited from Glindia Limited in year 1987 ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...